Dong-a St Co., Ltd.

Byung Jun Jang

Ji Hye Lee

Soon-Hoe Kim

Hyun Jung Kim

Seung Hyun Song

Eunjin Kim

Eun Jung Kim

Sung Pil Choi

Kyung Kyun Kang

Hyung Ki Lee

Ju Mi Kim

Hae Hum Jung

Chae Lim Ryu

Ji Hyun Sung

Jang Hyun Park

Kyung Koo Kang

Jae-Sung Hwang

Han Kook Chung

Byoung Hwa Son

Seul Min Choi

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.

Oxazolidine-based compound and selective androgen receptor agonist comprising same

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.

Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same

Growing community of inventors

Seoul, South Korea

Byung Jun Jang